Skip Navigation

Cardiovascular Research 2000 46(1):90-101; doi:10.1016/S0008-6363(99)00422-8
© 2000 by European Society of Cardiology
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Sussman, M. A.
Right arrow Articles by Molkentin, J. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sussman, M. A.
Right arrow Articles by Molkentin, J. D.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Copyright © 2000, European Society of Cardiology

Hypertrophic defect unmasked by calcineurin expression in asymptomatic tropomodulin overexpressing transgenic mice

Mark A. Sussmana,*, Sara Welcha, Angela Walkera, Raisa Klevitskya, Timothy E. Hewetta, Sandra A. Wittb, Thomas R. Kimballb, Robert Pricec, Hae W. Lima and Jeffery D. Molkentina

aThe Children's Hospital and Research Foundation, Division of Molecular Cardiovascular Biology, Room 3033, 3333 Burnet Avenue, Cincinnati, OH 45229, USA
bThe Children's Hospital and Research Foundation, Division of Cardiology, 3333 Burnet Avenue, Cincinnati, OH 45229, USA
cUniversity of South Carolina, Department of Cell Biology and Anatomy, Columbia, SC, USA

* Corresponding author. Tel.: +1-513-636-7145; fax: +1-513-636-8966 sussman{at}heart.chmcc.org

Objective: Dilation and hypertrophy often occur concurrently in cardiomyopathy, yet the interaction between these two functionally distinct conditions remains unknown. Methods: Combinatorial effects of hypertrophy and dilation were investigated by cross-breeding of two cardiomyopathic transgenic mouse lines which develop either hypertrophy (calcineurin-mediated) or dilation (tropomodulin-mediated). Results: Altering the intensity of signals driving hypertrophy and dilation in cross-bred litters resulted in novel disease phenotypes different from either parental line. Augmenting the calcineurin-dependent hypertrophic stimulus in tropomodulin overexpressing transgenics elevated heart:body weight ratios, increased ventricular wall thickness, and significantly accelerated mortality. These effects were evident in calcineurin cross-breeding to tropomodulin backgrounds of transgene homozygosity (severe dilation) or heterozygosity (mild dilation to asymptomatic). Molecular analyses indicated that tropomodulin and calcineurin signaling events in the first week after birth were critical for determination of disease outcome, substantiated by demonstration that temporary neonatal inhibition of tropomodulin expression prevents dilation. Conclusions: This study shows that postnatal timing of altered signaling in cardiomyopathic transgenic mouse models is a pivotal part of determining outcome. In addition, intensifying hypertrophic stimulation exacerbates dilated cardiomyopathy, supporting the concept of shared molecular signaling between hypertrophy and dilation.

KEYWORDS Cardiomyopathy; Contractile function; Heart failure; Hypertrophy; Signal transduction


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
Circ. Res.Home page
C. R. McKeown, R. B. Nowak, J. Moyer, M. A. Sussman, and V. M. Fowler
Tropomodulin1 Is Required in the Heart but Not the Yolk Sac for Mouse Embryonic Development
Circ. Res., November 21, 2008; 103(11): 1241 - 1248.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
A. A. Domenighetti, Q. Wang, M. Egger, S. M. Richards, T. Pedrazzini, and L. M.D. Delbridge
Angiotensin II-Mediated Phenotypic Cardiomyocyte Remodeling Leads to Age-Dependent Cardiac Dysfunction and Failure
Hypertension, August 1, 2005; 46(2): 426 - 432.
[Abstract] [Full Text] [PDF]


Home page
J BiochemHome page
S. Mitsuhashi, N. Saito, K. Watano, K. Igarashi, S. Tagami, H. Shima, and K. Kikuchi
Defect of Delta-Sarcoglycan Gene Is Responsible for Development of Dilated Cardiomyopathy of a Novel Hamster Strain, J2N-k: Calcineurin/PP2B Activity in the Heart of J2N-k Hamster
J. Biochem., August 1, 2003; 134(2): 269 - 276.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
D. Dong, Y. Duan, J. Guo, D. E Roach, S. L Swirp, L. Wang, J.P Lees-Miller, R.S Sheldon, J. D Molkentin, and H. J Duff
Overexpression of calcineurin in mouse causes sudden cardiac death associated with decreased density of K+ channels
Cardiovasc Res, February 1, 2003; 57(2): 320 - 332.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
S. Welch, D. Plank, S. Witt, B. Glascock, E. Schaefer, S. Chimenti, A. M. Andreoli, F. Limana, A. Leri, J. Kajstura, et al.
Cardiac-Specific IGF-1 Expression Attenuates Dilated Cardiomyopathy in Tropomodulin-Overexpressing Transgenic Mice
Circ. Res., April 5, 2002; 90(6): 641 - 648.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
S. Baudet
Hypertrophy and dilation: a TOTally new story?
Cardiovasc Res, April 1, 2000; 46(1): 17 - 19.
[Full Text] [PDF]


Home page
Circ. Res.Home page
S. Welch, D. Plank, S. Witt, B. Glascock, E. Schaefer, S. Chimenti, A. M. Andreoli, F. Limana, A. Leri, J. Kajstura, et al.
Cardiac-Specific IGF-1 Expression Attenuates Dilated Cardiomyopathy in Tropomodulin-Overexpressing Transgenic Mice
Circ. Res., April 5, 2002; 90(6): 641 - 648.
[Abstract] [Full Text] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.